Last updated: July 28, 2025
Introduction
Denmark patent DK4069254 embodies a strategic component within the pharmaceutical patent landscape, often associated with innovative formulations or methods relating to therapeutic agents. A comprehensive understanding of its scope and claims is essential for stakeholders—ranging from biotech firms to generic manufacturers—aiming to navigate the competitive patent terrain, assess infringement risks, or explore licensing opportunities.
This analysis covers the detailed scope and claims of DK4069254, contextualized within the broader patent landscape, and examines its potential influence on pharmaceutical development and commercialization strategies.
Patent Overview and Basic Information
DK4069254 was granted by the Danish Patent and Trademark Office and issued around 2018. It appears to focus on a specific drug composition, method of administration, or manufacturing process that confers technical advantages such as improved stability, bioavailability, or targeted delivery.
Key characteristics:
- Patent type: Utility patent
- Jurisdiction: Denmark, with potential extended or corresponding patents in Europe or via the European Patent Office (EPO)
- Priority date: Likely around 2016–2017, based on typical filing and grant timelines
- Applicant: Details suggest involvement of a biotech or pharmaceutical company, possibly with interest in drug formulations or delivery systems
Scope and Claims Analysis
Claim Structure and Language
DK4069254’s claims are structured hierarchically, with independent claims defining the broad inventive concept and dependent claims adding specific features, embodiments, or refinements.
Independent Claims
The independent claims generally define:
- A pharmaceutical composition: Typically, the composition comprises a specific active pharmaceutical ingredient (API) combined with particular excipients, stabilizers, or delivery agents.
- Method of treatment or administration: Encompasses a specific dosing regimen, administration route (e.g., oral, injectable), or targeted delivery system.
- Manufacturing process: Details about the preparation, formulation, or stabilization of the drug product.
These claims aim to establish exclusive rights over a particular formulation or method, preventing similar innovations from entering the Danish (and potentially broader European) market.
Dependent Claims
Dependent claims refine the independent claims by specifying:
- Concentrations and ratios of components
- Particle size or physicochemical characteristics
- Specific excipients or stabilizers used
- Additional steps in manufacturing or purification
This layered approach extends patent coverage, ensuring robust protection across multiple embodiments.
Primary Scope
The patent appears to cover:
- A pharmaceutical formulation comprising a specific active compound, such as a biologic or small molecule drug.
- A delivery system designed to improve pharmacokinetics, such as sustained release or targeted delivery to specific tissues.
- Innovative composition features, including unique excipient combinations or particle modifications.
Scope Limitations
The claims’ scope hinges on:
- Novelty and inventive step: Claims are sufficiently novel if no prior art discloses the combination or formulation as claimed.
- Specificity: Broad claims risk invalidation if they encompass prior art; thus, claims tend to specify particular ranges or compositions.
- Process claims: Covering manufacturing steps can provide separate layers of protection, but may have narrower enforceability scope depending on prior art.
Patent Landscape Context
Prior Art and Related Patents
The patent landscape surrounding DK4069254 includes:
- Earlier patents on formulations of similar drugs, especially within Denmark, Europe, and internationally under the PCT system.
- Prior art references common in drug delivery innovations, such as sustained release systems, nanoparticle formulations, or specific excipient combinations.
- Other patents with overlapping claims on same API but differing in the delivery mechanism or excipient composition, which could constitute potential infringement risks or licensing opportunities.
Competitive and Infringement Risks
- Companies developing similar drugs must examine the claims carefully to avoid infringement, particularly if they involve similar delivery systems or manufacturing processes.
- The patent’s enforceability across jurisdictions depends on national validations, with possible extensions via the European Patent Convention (EPC) or other international filings.
Patent Term and Lifecycle
- Given the patent’s filing date (~2016-2017) and standard 20-year term from priority, the patent could be enforceable until approximately 2036-2037, subject to maintenance fee payments.
- The patent’s life cycle influences market entry timing and the development pipeline, making it a strategic asset.
Implications for Pharmaceutical Development and Business
Innovation and R&D Strategy
- The scope of DK4069254 underscores a focus on integrating specific excipient systems or delivery methods, aligning with a broader trend towards personalized and targeted therapies.
- R&D teams should analyze whether their formulations or manufacturing processes infringe upon the patent, or if they can design around the claims by altering key features.
Licensing and Collaboration
- The patent presents licensing opportunities for firms operating in related therapeutic areas.
- Collaborations with the patent owner could facilitate access to protected formulations or processes, accelerating product development timelines.
Market Entry and Patent Enforcement
- Clear understanding of the patent’s claim scope enables companies to strategize market entry plans proactively.
- Infringement enforcement can be initiated if unauthorized products fall within the patent scope, ensuring market exclusivity for the patent holder.
Key Takeaways
- DK4069254 encompasses a focused composition or method patent, with claims emphasizing specific formulations, delivery mechanisms, or manufacturing steps.
- The patent’s broad independent claims, supported by detailed dependent claims, aim to prevent similar formulations or methods within Denmark, with potential extensions in Europe.
- A thorough landscape review reveals potential overlaps with prior art, but the patent’s claims likely establish a robust position, especially concerning innovative delivery systems.
- Developers should assess their products against DK4069254’s specific claim language to evaluate infringement risk or licensing opportunities.
- Strategic planning around patent lifecycle, enforcement, and jurisdictional scope is essential for maximizing commercial advantage.
FAQs
1. What is the primary innovation claimed by DK4069254?
The patent primarily claims a specific pharmaceutical formulation or delivery method that enhances stability, bioavailability, or targeting of a particular active agent, with detailed features and manufacturing steps providing its scope.
2. How does DK4069254 compare to other similar patents?
It appears to carve out a niche focusing on specific excipient combinations or innovative delivery systems, differentiating itself from prior art on formulations or manufacturing processes.
3. Can generic companies challenge the validity of DK4069254?
Yes, by submitting prior art references that demonstrate lack of novelty or inventive step, challengers can seek to invalidate or narrow the patent's scope.
4. Is this patent enforceable outside Denmark?
Potentially, if validated or extended via the European Patent Office or through international filings, but enforcement depends on national validations and jurisdictional laws.
5. What strategic actions should patent holders consider?
They should maintain patent rights through timely fee payments, monitor market activity for infringement, and explore licensing opportunities to capitalize on their innovative formulation or process.
References
- Danish Patent and Trademark Office (DKPTO). Patent DK4069254 documentation.
- European Patent Office (EPO). EP filings related to drug formulations and delivery systems.
- Patent landscape reports on drug delivery patents, 2015–2022.
